Huibin M. Zhang

State Key Laboratory Of Natural Medicines, 24 Tongjiaxiang, Nanjing 210009, PR China
Puerto Rico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Recent progress in small-molecule targeted therapies for melanoma treatment.

Recent progress in small-molecule targeted therapies for melanoma treatment.

Journal: Bioorganic & medicinal chemistry

Published: February 27, 2026

Design, synthesis, and evaluation of furo[3,2-c]pyridine-based MNK1/2 inhibitors for the treatment of colorectal cancer.

Design, synthesis, and evaluation of furo[3,2-c]pyridine-based MNK1/2 inhibitors for the treatment of colorectal cancer.

Journal: European journal of medicinal chemistry

Published: February 23, 2026

Design, Synthesis, and Performance Characterization of BODIPY-Based NIR Probes for Aβ42 Aggregate Detection.

Design, Synthesis, and Performance Characterization of BODIPY-Based NIR Probes for Aβ42 Aggregate Detection.

Journal: ChemPlusChem

Published: February 14, 2026

Dual BRD4/AKT inhibition overcomes c-MYC-driven resistance in metastatic castration-resistant prostate cancer.

Dual BRD4/AKT inhibition overcomes c-MYC-driven resistance in metastatic castration-resistant prostate cancer.

Journal: European journal of medicinal chemistry

Published: February 12, 2026

Design, Synthesis, and Biological Evaluation of Small-Molecule PD-1/PD-L1 Inhibitors Bearing a Rigid Benz[d]oxazole Skeleton.

Design, Synthesis, and Biological Evaluation of Small-Molecule PD-1/PD-L1 Inhibitors Bearing a Rigid Benz[d]oxazole Skeleton.

Journal: ChemMedChem

Published: January 22, 2026

Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint.

Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint.

Journal: ACS medicinal chemistry letters

Published: January 22, 2026

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia.

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia.

Journal: European journal of medicinal chemistry

Published: November 23, 2025

Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.

Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.

Journal: Journal of medicinal chemistry

Published: April 02, 2024

Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators.

Design, Synthesis, and Biological Evaluation of Eukaryotic Initiation Factor 2B (eIF2B) Activators.

Journal: ChemMedChem

Published: December 18, 2023

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects.

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects.

Journal: European journal of medicinal chemistry

Published: November 13, 2023

Design, synthesis and biological evaluation of MNK-PROTACs.

Design, synthesis and biological evaluation of MNK-PROTACs.

Journal: Molecular diversity

Published: October 10, 2023

Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.

Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.

Journal: European journal of medicinal chemistry

Published: April 01, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026